Clinical Trials Data from Pharma Butrans Presented at APS Annual Meeting

Purdue Pharma L.P. will demonstrate an analysis of data from completed clinical trials for Butrans Transdermal System CIII with the American Pain Society's (APS) 31st Annual Scientific Seminar. The research has an evaluation of supplemental analgesic use and pain marks along the 7-day dosing interval.

The poster will probably be presented with the APS meeting in Honolulu, HI on Friday, May 18 at 8:45 AM HAST: Butrans (buprenorphine) Transdermal Structure and 7-day Analgesic Performance.

Butrans is indicated for the administration of moderate-to-severe chronic pain in affected individuals requiring endless, hysterical opioid analgesic for some time. Accepted by the U.S. Food and Drug Administration (FDA) in June 2010, Butrans is the first transdermal structure that in fact delivers steady release of a typical active component, buprenorphine, for one week.

Butrans is a Schedule III opioid medication and might be abused in a manner similar to other opioid agonists, official or illicit. Engaging with the FDA, Purdue Pharma L.P. created a Risk Evaluation and Mitigation Strategy (REMS) for Butrans that includes a Treatment Guide, Factors to make certain Safe Use, for instance a healthcare provider training manual, and a timetable for submitting evaluations of typical REMS.